Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy

Grall‐Bronnec, Marie; Sauvaget, Anne; Perrouin, Fanny; Leboucher, Juliette; Etcheverrigaray, François; Challet-Bouju, Gaëlle; Gaboriau, Louise; Derkinderen, Pascal; Jolliet, Pascale; Victorri-Vigneau, Caroline

doi:10.1097/jcp.0000000000000444

Cited by 39 publications

(26 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While still controversial, receptor homeostatic compensation is not typically associated with chronic exposure to partial agonists (Varela et al., ; Gao et al., ), and initial reports for aripiprazole promoted this as an attractive feature for long‐term aripiprazole therapy (Burris et al., ). Nonetheless, as reported for full, direct‐acting dopamine agonists (Voon et al., ), ICSD are identified in some patients chronically treated with aripiprazole (Desarkar et al., ; Mouaffak et al., ; Schlachetzki & Langosch, ; Gavaudan et al., ; Kodama & Hamamura, ; Roxanas, ; Cohen et al., ; Smith et al., ; Cheon et al., ; Gaboriau et al., ; Moore et al., ; Bulbena‐Cabre & Bulbena, ; Grall‐Bronnec et al., ; Mahapatra et al., ; Das et al., ; Dhillon et al., ; Etminan et al., ; Gupta et al., ; Mohan et al., ; Peterson & Forlano, ; Reddy et al., ; Lertxundi et al., ). It is noteworthy that these effects may be more frequently associated with higher doses or aripiprazole (Mahapatra et al., ).…”

Section: Functional Neuroanatomymentioning

confidence: 86%

“…Nonetheless, as reported for full, direct-acting dopamine agonists (Voon et al, 2017), ICSD are identified in some patients chronically treated with aripiprazole (Desarkar et al, 2007;Mouaffak et al, 2007;Schlachetzki & Langosch, 2008;Gavaudan et al, 2010;Kodama & Hamamura, 2010;Roxanas, 2010;Cohen et al, 2011;Smith et al, 2011;Cheon et al, 2013;Gaboriau et al, 2014;Moore et al, 2014;Bulbena-Cabre & Bulbena, 2016;Grall-Bronnec et al, 2016;Mahapatra et al, 2016;Das et al, 2017;Dhillon et al, 2017;Etminan et al, 2017;Gupta et al, 2017;Mohan et al, 2017;Peterson & Forlano, 2017;Reddy et al, 2017;Lertxundi et al, 2018). It is noteworthy that these effects may be more frequently associated with higher doses or aripiprazole (Mahapatra et al, 2016).…”

Section: The Mystery Of Aripiprazolementioning

confidence: 88%

See 1 more Smart Citation

Pharmacological insights into impulsive‐compulsive spectrum disorders associated with dopaminergic therapy

Napier

Persons

2018

Eur J of Neuroscience

View full text Add to dashboard Cite

Impulsive‐compulsive spectrum disorders are associated with dopamine agonist therapy in some patients. These untoward outcomes occur with direct‐acting, full and partial agonists at D2 dopamine family receptors. The disorders typically emerge during chronic treatment, and exhibit common features that are independent of the neurological or psychiatric pathology for which the initial therapy was indicated. It is well‐documented that the brain is ‘plastic’, changing in response to alterations to internal factors (e.g., disease processes), as well as external factors (e.g., therapies). The complexities of these clinical scenarios have eluded a clear depiction of the neurobiology for impulsive‐compulsive spectrum disorders and engendered considerable debate regarding the mechanistic underpinnings of the disorders. In this opinion, we use pharmacological concepts related to homeostatic compensation subsequent to chronic receptor activation to provide a unifying construct. This construct helps explain the occurrence of impulsive‐compulsive spectrum disorders across disease states, and during therapy with full and partial agonists.

show abstract

Section: Functional Neuroanatomymentioning

confidence: 86%

Section: The Mystery Of Aripiprazolementioning

confidence: 88%

Pharmacological insights into impulsive‐compulsive spectrum disorders associated with dopaminergic therapy

Napier

Persons

2018

Eur J of Neuroscience

View full text Add to dashboard Cite

show abstract

“…Other studies systematically comparing different dopamine agonists have found no significant difference between each of them (Weintraub et al ., ; Gallagher et al ., ). Recent research also shows a strong effect of aripiprazole, prescribed for the treatment of mood disorders and schizophrenia, with stronger gambling‐related cognition in comparison to other dopamine agonists (Grall‐Bronnec et al ., ).…”

Section: Association With Parkinson's Disease Therapymentioning

confidence: 97%

Pathological gambling in Parkinson's disease: what are the risk factors and what is the role of impulsivity?

Heiden

Heinz

Romanczuk-Seiferth

2016

Eur J of Neuroscience

View full text Add to dashboard Cite

The incidence of pathological gambling in Parkinson's patients is significantly greater than in the general population. A correlation has been observed between dopamine agonist medication and the development of pathological gambling. However, scientists conjecture that the affected patients have underlying risk factors. Studies analysing Parkinson's patients have detected that patients who developed pathological gambling are younger, score higher on novelty-seeking tests, are more impulsive and are more likely to have a personal or family history of alcohol addiction. In addition, some genetic variations have been associated with the susceptibility of developing pathological gambling, which include mutations of DRD3, 5-HTTLPR and GRIN2B. Studies focusing on neurofunctional discrepancies between Parkinson's patients with and without pathological gambling have found increased functional activation and dopamine release in regions associated with the mesolimbic reward system. Furthermore, there is also evidence showing increased processing of reward and decreased activation elicited by punishment, suggesting altered learning processes. Furthermore, the role of deep brain stimulation of the nucleus subthalamicus (STN DBS) is controversial. In most Parkinson's patients, pathological gambling resolved after the initiation of the STN DBS, which might be explained by discontinuation or decrease in dopamine agonist medication. However, it has been also shown that some patients are more impulsive while the STN DBS is activated. These differences may depend on the DBS localization in the more limbic or motor part of the STN and their regulative effects on impulsivity. Further research is needed to clarify susceptibility factors for the development of pathological gambling in Parkinson's patients.

show abstract

“…These first cases were considered to be iatrogenic based on chronological and pharmacological arguments: (i) they appeared after the onset of PD and dopamine replacement therapy (DRT) initiation and disappeared after discontinuing DRT; and (ii) DRT acted on dopamine receptors in both the nigrostriatal pathway and the reward pathway, which plays a role in addictive behavior. Several reviews have compiled published case reports or case series [ 8 , 9 ] on this topic. Reported impulsive behaviors were pathological gambling, hypersexuality, compulsive shopping, binge eating, obsessive hobbying, punding, and compulsive medication use.…”

Section: Introductionmentioning

confidence: 99%

Dopamine Agonists and Impulse Control Disorders: A Complex Association

Grall‐Bronnec¹,

Victorri-Vigneau²,

Donnio³

et al. 2017

Drug Saf

Self Cite

114

103

View full text Add to dashboard Cite

Impulse control disorders (ICDs) are a well-known adverse effect of dopamine agonists (DAAs). This critical review aims to summarize data on the prevalence and factors associated with the development of an ICD simultaneous to DAA use. A search of two electronic databases was completed from inception to July 2017. The search terms were medical subject headings (MeSH) terms including “dopamine agonists” AND “disruptive disorders”, “impulse control disorders”, or “conduct disorders”. Articles had to fulfill the following criteria to be included: (i) the target problem was an ICD; (ii) the medication was a dopaminergic drug; and (iii) the article was an original article. Of the potential 584 articles, 90 met the criteria for inclusion. DAAs were used in Parkinson’s disease (PD), restless legs syndrome (RLS) or prolactinoma. The prevalence of ICDs ranged from 2.6 to 34.8% in PD patients, reaching higher rates in specific PD populations; a lower prevalence was found in RLS patients. We found only two studies about prolactinoma. The most robust findings relative to the factors associated with the development of an ICD included the type of DAA, the dosage, male gender, a younger age, a history of psychiatric symptoms, an earlier onset of disease, a longer disease duration, and motor complications in PD. This review suggests that DAA use is associated with an increased risk in the occurrence of an ICD, under the combined influence of various factors. Guidelines to help prevent and to treat ICDs when required do exist, although further studies are required to better identify patients with a predisposition.

show abstract

Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy

Abstract: Supplemental digital content is available in the text.

Cited by 39 publications

References 75 publications

Pharmacological insights into impulsive‐compulsive spectrum disorders associated with dopaminergic therapy

Pharmacological insights into impulsive‐compulsive spectrum disorders associated with dopaminergic therapy

Pathological gambling in Parkinson's disease: what are the risk factors and what is the role of impulsivity?

Dopamine Agonists and Impulse Control Disorders: A Complex Association

Contact Info

Product

Resources

About